Patent ductus arteriosus closure using Occlutech® Duct Occluder, experience in Port Elizabeth, South Africa

Background: Percutaneous closure of patent ductus arteriosus (PDA) has become standard therapy. Experience with the Occlutech® Duct Occluder is limited. Methods: Data regarding ductal closure using Occlutech® Duct Occluder were reviewed and prospectively collected. Demographics, hemodynamic and angi...

Full description

Bibliographic Details
Main Authors: Lungile Pepeta, Adele Greyling, Mahlubandile Fintan Nxele, Zongezile Masonwabe Makrexeni
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Annals of Pediatric Cardiology
Subjects:
Online Access:http://www.annalspc.com/article.asp?issn=0974-2069;year=2017;volume=10;issue=2;spage=131;epage=136;aulast=Pepeta
id doaj-b70c0704b691482593d3808e8830f898
record_format Article
spelling doaj-b70c0704b691482593d3808e8830f8982020-11-24T23:14:56ZengWolters Kluwer Medknow PublicationsAnnals of Pediatric Cardiology0974-20692017-01-0110213113610.4103/0974-2069.205144Patent ductus arteriosus closure using Occlutech® Duct Occluder, experience in Port Elizabeth, South AfricaLungile PepetaAdele GreylingMahlubandile Fintan NxeleZongezile Masonwabe MakrexeniBackground: Percutaneous closure of patent ductus arteriosus (PDA) has become standard therapy. Experience with the Occlutech® Duct Occluder is limited. Methods: Data regarding ductal closure using Occlutech® Duct Occluder were reviewed and prospectively collected. Demographics, hemodynamic and angiographic characteristics, complications, and outcomes were documented. Results: From March 2013 to June 2016, 65 patients (43 females and 22 males) underwent percutaneous closure of the PDA using Occlutech® Duct Occluder. The median age of the patients was 11 months (range, 1–454 months) and the median weight was 8.5 kg (range 2.5–78 kg). The mean pulmonary artery median pressure was 27 mmHg (range, 12–100 mmHg) and the QP: Qs ratio median was 1.8 (range, 1–7.5), with a pulmonary vascular resistance mean of 2.7 WU (standard deviation [SD] ±2.1). Thirty-two patients had Krichenko Type A duct (49%); 7, Type C (11%); 4, Type D (6%); and 22, Type E (34%). The ductal size (narrowest diameter at the pulmonic end) mean was 3.5 mm (SD ± 1.9 mm). The screening time mean was 17.3 min (SD ± 11.6). Out of 63 patients with successful closure of the PDA using Occlutech® Duct Occluder, there were 15 patients with small PDAs; 25 with moderate PDAs, and 23 with large PDAs. In one patient, the device dislodged to the descending aorta, and in two patients, to the right pulmonary artery immediately following deployment, with successful percutaneous (two) and surgical (one) retrieval. Complete ductal occlusion was achieved in all 63 patients on day one. Conclusion: The Occlutech® Duct Occluder is a safe and effective device for closure of ducts in appropriately selected patients.http://www.annalspc.com/article.asp?issn=0974-2069;year=2017;volume=10;issue=2;spage=131;epage=136;aulast=PepetaOcclutech devicepatent ductus arteriosuspercutaneous occlusion
collection DOAJ
language English
format Article
sources DOAJ
author Lungile Pepeta
Adele Greyling
Mahlubandile Fintan Nxele
Zongezile Masonwabe Makrexeni
spellingShingle Lungile Pepeta
Adele Greyling
Mahlubandile Fintan Nxele
Zongezile Masonwabe Makrexeni
Patent ductus arteriosus closure using Occlutech® Duct Occluder, experience in Port Elizabeth, South Africa
Annals of Pediatric Cardiology
Occlutech device
patent ductus arteriosus
percutaneous occlusion
author_facet Lungile Pepeta
Adele Greyling
Mahlubandile Fintan Nxele
Zongezile Masonwabe Makrexeni
author_sort Lungile Pepeta
title Patent ductus arteriosus closure using Occlutech® Duct Occluder, experience in Port Elizabeth, South Africa
title_short Patent ductus arteriosus closure using Occlutech® Duct Occluder, experience in Port Elizabeth, South Africa
title_full Patent ductus arteriosus closure using Occlutech® Duct Occluder, experience in Port Elizabeth, South Africa
title_fullStr Patent ductus arteriosus closure using Occlutech® Duct Occluder, experience in Port Elizabeth, South Africa
title_full_unstemmed Patent ductus arteriosus closure using Occlutech® Duct Occluder, experience in Port Elizabeth, South Africa
title_sort patent ductus arteriosus closure using occlutech® duct occluder, experience in port elizabeth, south africa
publisher Wolters Kluwer Medknow Publications
series Annals of Pediatric Cardiology
issn 0974-2069
publishDate 2017-01-01
description Background: Percutaneous closure of patent ductus arteriosus (PDA) has become standard therapy. Experience with the Occlutech® Duct Occluder is limited. Methods: Data regarding ductal closure using Occlutech® Duct Occluder were reviewed and prospectively collected. Demographics, hemodynamic and angiographic characteristics, complications, and outcomes were documented. Results: From March 2013 to June 2016, 65 patients (43 females and 22 males) underwent percutaneous closure of the PDA using Occlutech® Duct Occluder. The median age of the patients was 11 months (range, 1–454 months) and the median weight was 8.5 kg (range 2.5–78 kg). The mean pulmonary artery median pressure was 27 mmHg (range, 12–100 mmHg) and the QP: Qs ratio median was 1.8 (range, 1–7.5), with a pulmonary vascular resistance mean of 2.7 WU (standard deviation [SD] ±2.1). Thirty-two patients had Krichenko Type A duct (49%); 7, Type C (11%); 4, Type D (6%); and 22, Type E (34%). The ductal size (narrowest diameter at the pulmonic end) mean was 3.5 mm (SD ± 1.9 mm). The screening time mean was 17.3 min (SD ± 11.6). Out of 63 patients with successful closure of the PDA using Occlutech® Duct Occluder, there were 15 patients with small PDAs; 25 with moderate PDAs, and 23 with large PDAs. In one patient, the device dislodged to the descending aorta, and in two patients, to the right pulmonary artery immediately following deployment, with successful percutaneous (two) and surgical (one) retrieval. Complete ductal occlusion was achieved in all 63 patients on day one. Conclusion: The Occlutech® Duct Occluder is a safe and effective device for closure of ducts in appropriately selected patients.
topic Occlutech device
patent ductus arteriosus
percutaneous occlusion
url http://www.annalspc.com/article.asp?issn=0974-2069;year=2017;volume=10;issue=2;spage=131;epage=136;aulast=Pepeta
work_keys_str_mv AT lungilepepeta patentductusarteriosusclosureusingocclutechductoccluderexperienceinportelizabethsouthafrica
AT adelegreyling patentductusarteriosusclosureusingocclutechductoccluderexperienceinportelizabethsouthafrica
AT mahlubandilefintannxele patentductusarteriosusclosureusingocclutechductoccluderexperienceinportelizabethsouthafrica
AT zongezilemasonwabemakrexeni patentductusarteriosusclosureusingocclutechductoccluderexperienceinportelizabethsouthafrica
_version_ 1725592824167006208